First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients

Lung-Yi Mak¹,², Danny Ka-Ho Wong¹,², Ka-Shing Cheung¹,³, Wai-Kay Seto¹,², James Fung¹,² and Man-Fung Yuen¹,² *

Abstract
Background: Serum hepatitis B core-related antigen (HBcrAg) is a potential surrogate marker for intra-hepatic covalently-closed circular DNA in chronic hepatitis B (CHB). We aimed to study the profiles of serum HBcrAg in CHB patients treated with first-line nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF).

Method: Serum HBcrAg was measured in 120 treatment-naïve CHB patients receiving one of the 3 NAs (ETV: TDF: TAF = 60: 26: 34) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan). Serum HBcrAg levels were measured at week 0, week 48 and week 96 of NA therapy.

Results: Among the 120 patients, 67 (55.8%) were hepatitis B e antigen (HBeAg) positive. Both tenofovir and ETV led to significantly lower serum HBcrAg at week 48 and week 96 compared to week 0. There were no significant differences for the magnitude of median HBcrAg decline at week 96 between tenofovir and ETV in HBeAg-positive (2.28 vs. 1.65 log U/mL, p > 0.05) and HBeAg-negative (0.83 vs. 0.54 log U/mL, p > 0.05) patients. TDF and TAF produced no significant differences in the magnitude of median HBcrAg decline at week 96 (HBeAg-positive: 2.63 vs. 1.83, respectively; HBeAg-negative: 1.04 vs. 0.40, respectively; both p > 0.05).

Conclusion: Magnitude of reduction of HBcrAg levels after 2-year first-line treatment did not differ statistically among the current first-line NAs, although HBcrAg reduction was numerically greater in tenofovir-treated group. More long-term studies are essential to determine whether tenofovir exerts a more pronounced effect on HBcrAg.

Keywords: Hepatitis B, Entecavir, Tenofovir, Hepatitis B core-related antigen, Nucleotide analogue

Background
Chronic hepatitis B (CHB) infection affects 292 million worldwide and led to 0.88 million deaths as of year 2015 [1]. Liver-related mortality is attributed by the development of acute on chronic liver failure, decompensated cirrhosis and hepatocellular carcinoma (HCC) [2]. In the past two decades, nucleos(t)ide analogues (NAs) have led to a major paradigm shift in the management of patients with CHB. Through suppression of viral replicative activities, with subsequent cessation of hepatic necro-inflammation and fibrosis regression [3, 4], the risk of decompensated cirrhosis, HCC and mortality can be reduced [5–7]. In the current era, 3 NAs are considered to be first-line after considering the individual efficacy, resistance profile and risk of adverse events. These include tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) and entecavir (ETV), as...
recommended by the European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) guidelines [8, 9].

In the absence of direct head-to-head trials comparing these agents, their short-term potencies are assumed to be similar. For instance, in hepatitis B e antigen (HBeAg) positive patients, the rate of treatment induced HBeAg seroconversion at 1 year of therapy was 21%, 10% and 21% for TDF, TAF and ETV, respectively, with alanine aminotransferase (ALT) normalization rates of 68%, 72% and 68% respectively [8, 10]. However, there is emerging evidence to suggest that both short-term and long-term outcomes may differ between the various NAs. Firstly, in the phase 3 trials of TAF using TDF as a comparison, the proportion of patients with ALT normalization at week 96 was found to be higher for TAF than TDF [11]. It is postulated that the viral suppression potency is higher for TAF compared to TDF due to undefined mechanisms. Since no liver biopsies were performed in the trial, this hypothesis cannot be proven directly. Secondly, TDF has been shown to be associated with lower risk of HCC compared to ETV in a recent study and meta-analysis, while the underlying mechanisms for this phenomenon remains unknown [12, 13].

It is possible that different NAs may exert different effects on other viral replicative markers which may be important in HCC development. Higher hepatitis B core-related antigen (HBcrAg) levels, a reliable surrogate marker for intrahepatic covalently closed circular DNA (cccDNA), has been associated with higher risk of HCC in treatment-experienced CHB patients [14]. This may indicate a potential role of serum HBcrAg as a more sensitive marker in assessing the intrahepatic viral replicative activity especially in treated patients with suppressed serum HBV DNA [15]. We postulate that the 3 first-line NAs have different potency in reduction of intrahepatic cccDNA. In this study, we measured serially the serum HBcrAg as a surrogate marker of intrahepatic cccDNA, in patients treated with TDF, TAF and ETV.

**Methods**

**Patients**

We recruited treatment-naïve CHB patients from the Liver Clinic of Queen Mary Hospital, the University of Hong Kong, Hong Kong. All patients were seropositive for hepatitis B surface antigen for at least 6 months before treatment. Treatment-naïve patients, either HBeAg-positive or HBeAg-negative, who were newly started on NA were identified. For tenofovir, those with HBV DNA ≥ 20,000 IU/mL and serum ALT > 60 U/L (males) or > 38 U/L (females) were started on either TDF (300 mg daily) or TAF (25 mg daily). For ETV (0.5 mg daily), the indications for treatment with ETV were slightly different from tenofovir due to differences in local practice and were as follows: (1) HBeAg-positive non-cirrhotic patients with elevated ALT (upper limit of normal was defined as 50 U/L at that time) and HBV DNA > 20,000 IU/mL, or (2) HBeAg-negative non-cirrhotic patients with elevated ALT and HBV DNA > 2000 IU/mL, or (3) cirrhotic patients with detectable serum HBV DNA > 2000 IU/mL. Cirrhosis is defined by the presence of small nodular liver, splenomegaly, ascites, or varices in the porto-systemic circulation by ultrasound or computerized tomography. Patients were excluded if they were pregnant, or had concomitant hepatitis C or D virus, human immunodeficiency virus infection, Wilson’s disease, autoimmune hepatitis, primary biliary cholangitis, non-alcoholic steatohepatitis, or significant alcohol intake (20 g/day for female or 30 g/day for male). Clinical assessment and blood taking for liver biochemistry every 3–6 months were arranged for all recruited patients.

The present study was approved by the Institutional Review Board of the University of Hong Kong and the Hospital Authority Hong Kong West Cluster, Hong Kong.

**Laboratory assays**

Serum HBV DNA levels were detected and quantified using Cobas Taqman assay (Roche Diagnostics, Branchburg, NJ) with a lower limit of detection (LLOD) of 10 IU/mL. For the current study, undetectable serum HBV DNA was defined as < 29 IU/mL taking reference to the same definition used in the TAF registration trial [11].

HBcrAg consists of 3 related proteins: hepatitis B core antigen, HBeAg, and a truncated 22 kDa precore protein (p22cr), which all share an identical 149 amino acid sequences. The assay has been described elsewhere [16, 17]. Briefly, particles coated with anti-HBcrAg monoclonal antibodies are added to the specimen and allowed to form antigen–antibody immune-complexes, followed by alkaline phosphatase-labelled anti-HBcrAg binding to HBcrAg of the immune-complexes on the particles which allows additional immunocomplex formation. Quantification of HBcrAg is fully automated by comparing the chemiluminescence signals generated by known concentration of recombinant ProHBeAg [15]. Serum HBcrAg were measured by the Lumipulse G HBcrAg chemiluminescence Enzyme Immunoassay (Fujirebio, Tokyo, Japan). The dynamic range of the assays ranged from 100 to 10,000,000 unit per milliliter (U/mL). Undetectable serum HBcrAg is defined as < 0.1 log U/mL. The values of HBcrAg were log transformed and were expressed in log U/mL. Serum HBcrAg levels were measured at week 0, week 48 and week 96 of NA therapy.
Statistical analyses
Serum HBV DNA levels and HBcrAg levels were expressed in logarithm. Continuous variables were expressed in median (interquartile range). For the comparison between continuous variables, Mann–Whitney U test and Kruskal–Wallis test were used. Categorical variables were compared using Pearson’s χ² test or Fisher’s exact test as appropriate. Spearman’s correlation coefficient was analysed to assess the relationship between serum HBcrAg and HBV DNA. Comparison between tenofovir and ETV treatment was performed. Subgroup analysis between TDF and TAF was also performed. Since HBcrAg is relatively less expressed in HBeAg-negative compared to HBeAg-positive patients, all major analyses were performed in subgroups according to the HBeAg status. All statistical analyses were performed using SPSS version 25 (SPSS, Chicago, IL). A two-sided p value of < 0.05 was considered statistically significant.

Results
Baseline
One hundred and twenty treatment-naïve CHB patients were recruited. Sixty patients (HBeAg-positive: 43 vs. HBeAg-negative: 17) were started on tenofovir and 60 patients (HBeAg-positive: 24 vs. HBeAg-negative: 36) were started on ETV. Majority of patients had elevated ALT at baseline (85.8%). The baseline characteristics were similar between tenofovir and ETV group in the HBeAg-positive patients. In the HBeAg-negative subgroup, ETV-treated patients were younger (40.9 vs. 55 years, p = 0.004) and had significantly higher proportion of male patients compared to tenofovir-treated patients (80.6% vs. 64.7%, p = 0.002). There were no significant differences of median baseline serum HBcrAg between male and female patients (3.60 vs. 3.93 log U/mL; p = 0.875). Due to different indications of individual antiviral as mentioned in the Methods section, none of the tenofovir-treated patients had cirrhosis compared to 11.7% of ETV-treated patients. The baseline characteristics are shown in Table 1. All 120 patients had serial measurement of serum HBcrAg at week 0, 48 and 96. None of the patients developed HBsAg seroclearance during the study period. At 96 weeks, a total of 24 patients [14/43 (32.6%) tenofovir-treated vs. 10/24 (41.7%) ETV-treated] developed HBeAg seroclearance.

Kinetics of serum HBcrAg
The median serum HBcrAg was significantly higher in HBeAg-positive patients compared to HBeAg-negative patients in both treatment groups at all 3 time points (all p < 0.001) (Fig. 1). In each treatment group, median serum HBcrAg was significantly lower at week 48 and week 96 compared to week 0, regardless of the HBeAg positivity (Fig. 1). There were no significant differences in the median serum HBcrAg between tenofovir-treated and ETV-treated patients at week 48 and week 96 (for HBeAg-positive patients: p = 0.111 and p = 0.425, respectively; for HBeAg-negative patients: p = 0.295 and p = 0.176, respectively).

For HBeAg-positive patients, compared to week 0, tenofovir-treated patients had numerically greater decline in serum HBcrAg compared to ETV-treated patients at week 48 (1.53 vs. 1.2 log U/mL, p = 0.425) and week 96 (2.28 vs. 1.65 log U/mL, p = 0.209), although this was statistically insignificant. Compared to week 48, serum HBcrAg declined by 0.55 and 0.30 log U/mL at week 96 for tenofovir-treated and ETV-treated patients, respectively (p = 0.214) (Fig. 2). The degree of serum HBcrAg decline was greater in the first 48 weeks compared to the subsequent 48 weeks for both tenofovir (1.53 vs.

Table 1  Baseline parameters of 120 patients

|                              | All patients (N = 120) | HBeAg-positive (n = 67) | HBeAg-negative (n = 53) |
|------------------------------|------------------------|-------------------------|-------------------------|
|                              | TDF/TAF (n = 43)       | ETV (n = 24)            | TDF/TAF (n = 17)        | ETV (n = 36) |
| Age (years)                  | 42.9 (34.0–55.0)       | 38.0 (31.0–52.0)        | 43.8 (38.3–56.0)        | 55.0 (41.2–62.1) |
|                            | 0.136                  | 0.136                   | 0.036                   | 0.004         |
| Number of male patients      | 76 (63.3%)             | 25/43 (58.1%)           | 16/24 (66.7%)           | 11/17 (64.7%) |
|                            | 0.604                  | 0.604                   | 0.604                   | 0.002         |
| HBcrAg (log U/mL)            | 3.64 (2.24–5.23)       | 5.23 (4.36–5.63)        | 4.87 (3.40–5.34)        | 2.03 (1.35–2.70) |
|                            | 0.066                  | 0.066                   | 0.066                   | 0.517         |
| Percentage of patients with undetectable HBcrAg* | 0%                     | 0%                     | N/A                     | 0%          |
| ALT                          | 73 (53–138)            | 79 (58–144)             | 89 (49–304)             | 57 (46–79) |
|                            | 0.646                  | 0.646                   | 0.646                   | 0.099         |
| Percentage of patients with elevated ALT | 103/120 (85.8%)       | 37/43 (86.0%)           | 21/24 (87.5%)           | 16/17 (94.1%) |
| Percentage of patients with cirrhosis | 7/120 (5.8%)          | 0/43 (0%)               | 0/24 (0%)               | 0/17 (0%) |
|                            | 0.082                  | 0.082                   | 0.082                   | 0.082         |

Continuous variables were expressed as median (interquartile range) ALT: alanine aminotransferase, ETV: entecavir, HBcrAg: hepatitis B core-related antigen, HBeAg: hepatitis B e antigen, TAF: tenofovir alafenamide, TDF: tenofovir disoproxil fumarate

* Undetectable serum HBcrAg is defined as < 0.1 log U/mL
0.55 log U/mL, \( p > 0.05 \)) and ETV (1.2 vs. 0.3 log U/mL, \( p > 0.05 \)) treatment (Fig. 2).

Similar to HBeAg-positive patients, for HBeAg-negative patients, compared to week 0, tenofovir-treated patients had numerically greater decline in serum HBcrAg compared to ETV-treated patients at week 48 (0.51 vs. 0.33 log U/mL, \( p = 0.391 \)) and week 96 (0.83 vs. 0.54 log U/mL, \( p = 0.696 \)), although again this was statistically insignificant. Compared to week 48, serum HBcrAg declined by 0.06 and 0.22 log U/mL at week 96 for tenofovir-treated and ETV-treated patients, respectively (\( p = 0.256 \)) (Fig. 3). The degree of serum HBcrAg decline was greater in the first 48 weeks compared to
the subsequent 48 weeks for both tenofovir (0.51 vs. 0.06 log U/mL, \( p < 0.05 \)) and ETV (0.33 vs. 0.22 log U/mL, \( p > 0.05 \)) treatment (Fig. 3). Additional analysis for the relative reduction of HBcrAg from baseline (expressed in percentage) showed similar results in terms of statistically non-significant bigger magnitude of decline in tenofovir-treated patients compared to ETV-treated patients (Additional 1: Table S1).

All HBeAg-positive patients had detectable serum HBcrAg at all 3 time points. In contrast, the proportion of patients with detectable serum HBcrAg declined in HBeAg-negative patients for both treatment groups (Fig. 4). At week 48, serum HBcrAg was still detectable in 100% tenofovir-treated patients and 91.7% ETV-treated patients (\( p = 0.543 \)). At week 96, serum HBcrAg was still detectable in 94.1% tenofovir-treated patients and 88.9% ETV-treated patients (\( p = 1.00 \)).

**Subgroup analysis of TDF vs. TAF treated patients**

Twenty-six and 34 patients were treated with TDF (HBeAg-positive: negative = 18.8) and TAF (HBeAg-positive: negative = 25.9) respectively. Among tenofovir-treated HBeAg-positive patients, the median baseline serum HBcrAg were 5.37 and 5.07 log U/mL for TDF and TAF, respectively (\( p = 0.321 \)). There were no significant differences between the median baseline serum HBV DNA between TDF and TAF (8.04 vs. 8.04 log U/mL, respectively, \( p = 0.492 \)). Serum HBcrAg showed strong linear correlation with serum HBV DNA (\( r = 0.78, p < 0.001 \)). Upon antiviral treatment, the decline of serum HBcrAg at week 48 and week 96 showed no statistical significance between the 2 treatment groups (Additional 1: Table S2). Serum HBcrAg still showed linear, albeit weaker, correlation with serum HBV DNA at week 48 (\( r = 0.80, p < 0.001 \)). There was no correlation between these two viral markers at week 96 (\( r = 0.149, p = 0.366 \)).

Among tenofovir-treated HBeAg-negative patients, the median baseline serum HBcrAg were 2.15 vs. 1.44 log U/mL for TDF and TAF, respectively (\( p = 0.301 \)). There were no significant differences between the median baseline serum HBV DNA between TDF and TAF (5.60 vs. 5.22 log U/mL, respectively, \( p = 0.673 \)). Serum HBcrAg showed strong linear correlation with serum HBV DNA (\( r = 0.80, p < 0.001 \)). Upon antiviral treatment, the decline at week 48 and week 96 showed no statistical significance between the 2 treatment groups (Additional 1: Table S2). Serum HBcrAg still showed linear, albeit weaker, correlation with serum HBV DNA at week 48 (\( r = 0.643, p = 0.005 \)). There was no correlation between these two viral markers at week 96 (\( r = 0.122, p = 0.642 \)).

The antiviral efficacies of TDF and TAF are shown in Additional 1: Table S3. ‘ALT normalization’ was defined as patients who had ALT higher than upper limit of normal (ULN) (> 40 U/L or > 30 U/L for males and > 19 U/L for females according to the EASL and AASLD guideline respectively) [8, 9] at baseline and subsequently had normal ALT at week 48 or 96. Using the EASL definition of normal ALT, there were no significant differences in ALT normalization between TDF and TAF in both HBeAg-positive (93.8% in TDF vs. 95.2% in TAF, \( p = 0.733 \)) and HBeAg-negative patients (85.7% in TDF vs. 87.5% in TAF, \( p = 0.833 \)) at week 96. Similarly, using AASLD definition of normal ALT, there were no significant differences in ALT normalization between TDF and TAF in both HBeAg-positive (61.1% in TDF vs. 50.0% in TAF, \( p = 0.542 \)) and HBeAg-negative patients (25.0% in TDF vs. 44.4% in TAF, \( p = 0.620 \)) at week 96.

**Discussion**

This study compared the antiviral efficacies in suppression of serum HBcrAg between the 3 first line NAs—TDF, TAF and ETV, in patients with HBeAg-positive chronic hepatitis or HBeAg-negative chronic hepatitis. All 3 NAs showed significant suppression of viral activity, as evidenced by serum HBcrAg reduction, which was already evident at week 48 of treatment and with continued suppression through to week 96. The rate of serum HBcrAg decline was faster during the initial 48 weeks compared to the subsequent 48 weeks, which is a consistent finding with previous report [18]. To the best of our knowledge, this is the first study in the literature that investigated the serum HBcrAg profile in TAF-treated patients, and the relative efficacy of each NA in serum HBcrAg suppression.

There was modest linear correlation between HBcrAg and HBV DNA even at 48 weeks of tenofovir treatment. No more correlation could be observed at week 96.
as > 90% already had undetectable HBV DNA. Despite a high rate of achieving serum HBV DNA undetectability in both tenofovir and ETV-treated patients at 96 weeks, majority of them still had detectable serum HBcAg (94.1% and 88.9%, respectively; \( p = 1.00 \)). Since the rate of serum HBcAg decline was reported to be 0.244 kU/mL/year in ETV-treated patient in a 7-year study [18], a longer treatment duration will be needed to bring down serum HBcAg to below the lower limit of detection.

There were no significant differences in the efficacies between tenofovir and ETV, although numerically a greater decline in serum HBcAg was observed in tenofovir-treated group. However, the current study may be under-powered to detect a significant difference due to the limited number of patients recruited in each group. In addition, it would be important to determine whether this differential reduction of HBcAg may become significant if the comparison is made upon more long-term treatment. The higher proportion of undetectable serum HBcAg in ETV-treated group at week 48 and 96 (fig. 4) may be due to the fact that there was a higher proportion of HBeAg-negative patients compared to tenofovir-treated group [36/60 (60%) vs. 17/60 (28.3%), \( p < 0.001 \)], and is thus unlikely to reflect stronger suppression of HBcAg by ETV. It was previously reported that serum HBcAg is negatively correlated with age (\( r = -0.505, p < 0.001 \)) in 139 treatment-naïve Chinese CHB patients [19], but another study reported no significant correlation (\( r = -0.25, p = 0.068 \)) between age and serum HBcAg in 54 similarly treatment-naïve Chinese CHB patients [16]. In the current study, the age difference between tenofovir-treated and ETV-treated groups was not statistically significant [42 (IQR 32–55) vs 43.5 (IQR 36.2–53), \( p = 0.998 \)], and thus the effect of age on serum HBcAg is unclear.

In a recent study of CHB patients treated with ETV and TDF for 5 years, no significant difference was observed with regards to the reduction in the risk of mortality, liver transplantation and hepatic decompensation [20]. The results of the current study somewhat provide more mechanistic insights at the fact that all 3 first-line NAs are equally effective in improving the outcomes of CHB patients. It still remains controversial whether TDF is more potent in the prevention of HCC compared to ETV. HBcAg had been reported to be a biomarker to predict HCC development in NA-treated patients. The results from the current study did not favour tenofovir as a stronger NA compared to ETV at suppressing serum HBcAg, which might be associated with lower risk of HCC. However, 2 years is a relatively short duration and is not able to answer this question. A longer duration of NA treatment will be necessary to observe any divergence in viral activity suppression with relevance to reduction in HCC risk.

The rate of ALT normalization at week 96 was similar between TDF and TAF in both HBeAg-positive (93.8% and 95.2%, respectively) and HBeAg-negative (85.7% and 87.5%, respectively) patients. This finding was different from a previous study which reported the 96-week outcome for the 2 phase III trials of TAF (n = 792 and n = 395 for HBeAg-positive patients and HBeAg-negative patients, respectively) [11]. This could be due to the different definition of ‘ALT normalization’ used in the current study (ALT > 40 U/L) in contrast to that used in the phase III trials (ALT > 30 U/L for male and > 19 U/L for female). Since the ULN in the current study is higher, it is relatively easier to achieve ‘normalization’ and therefore the rates were higher compared to that reported in Agarwal et al. (HBeAg-positive: 42% in TDF vs. 52% in TAF, \( p = 0.003 \); HBeAg-negative: 40% in TDF vs. 50% in TAF, \( p = 0.035 \)). In the current study, if the same AASLD definition was used, the rates of ALT normalization at week 96 were similar in either HBeAg-positive patients (61.1% in TDF vs. 50.0% in TAF, \( p = 0.542 \)) and HBeAg-negative patients (25.0% in TDF vs. 44.4% in TAF, \( p = 0.620 \)). There were still no statistically significant differences between TDF and TAF for ALT normalization. Nevertheless, the sample size is much smaller in the current study (n = 43 and n = 17 for HBeAg-positive patients and HBeAg-negative patients, respectively). This finding is in parallel with the fact that there were no subgroup differences in terms of HBcAg suppression between TDF and TAF.

There were several limitations in the current study. First, liver biopsies were not performed to assess the reduction in intrahepatic cccDNA and HBV DNA. However, liver biopsies may carry sampling errors and are not without risks. Nevertheless, the surrogacy of serum HBcAg with intrahepatic cccDNA has been well described (\( r = 0.664–0.7 \)) [15, 16, 21], and CHB patients may avoid this invasive procedure for the purpose of measuring cccDNA activity. Secondly, the follow-up duration was only up to 96 weeks. Long term follow-up and longitudinal measurement of serum HBcAg would be important to ascertain the sustained virological suppression and observe any between group differences of tenofovir and ETV, in addition to the impact on improving clinical outcomes. Thirdly, the small sample size may preclude the findings of a significant difference between the treatment groups.

**Conclusion**

The magnitude of reduction of HBcAg levels after 2-year first line treatment did not differ statistically among the current first line NAs, although HBcAg reduction was numerically greater in tenofovir treated
group. More long-term treatment studies are essential to determine whether tenofovir would exert a more pronounced effect on HBcrAg.

Abbreviations
CHB: Chronic hepatitis B; HCC: Hepatocellular carcinoma; NAs: Nucleos(t)ide analogues; TDF: Tenofovir disoproxil fumarate; TAF: Tenofovir alafenamide; ETV: Entecavir; EASL: European Association for the Study of the Liver; AASLD: American Association for the Study of Liver Diseases; HBsAg: Hepatitis B e antigen; ALT: Alanine aminotransferase; HBcrAg: Hepatitis B core-related antigen; cccDNA: Covalently-closed circular DNA.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-021-01711-x.

Additional file 1: Supplementary material.

Acknowledgements
None.

Authors' contributions
LYM was responsible for data analysis, interpretation, statistical analysis and drafting of the manuscript. DKW was responsible for data acquisition, data interpretation and critical revision of the manuscript. KSC was responsible for verification and review of data and statistical analysis. WKS and JF were responsible for critical revision of the manuscript and technical support. MFY was responsible for study concept and design, critical revision of the manuscript, and study supervision. All authors have read and approved the manuscript.

Funding
This study was not funded.

Availability of data and materials
The dataset used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The present study was approved by the Institutional Review Board of the University of Hong Kong and the Hospital Authority Hong Kong West Cluster, Hong Kong. All subjects provided written informed consent to participate.

Consent for publication
Not applicable.

Competing interests
LYM is an advisory board member for Gilead Sciences. WKS received speaker fees, is an advisory board member and received research funding from Gilead Sciences. MFY served as advisor/ consultant for and received grant/ research supports from Gilead Sciences. DKW and JF have no potential conflict of interest to disclose.

Author details
1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102, Pok Fu Lam, Hong Kong. 2 State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong. 3 Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.

Received: 27 May 2020 Accepted: 7 March 2021
Published online: 17 March 2021

References
1. Polaris OC. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.
2. Fattovich G. Natural history of hepatitis B. J Hepatol. 2003;39(Suppl 1):S50–8.
3. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–93.
4. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.
5. Nguyen MH, Yang HI, Le A, et al. Reduced Incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir-a propensity score-matched study. J Infect Dis. 2019;219:10–8.
6. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.
7. Garg H, Saini SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.
8. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(6):370–98.
9. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
10. Chan HT, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185–95.
11. Agarwal K, Brunetto M, Seto WK, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672–81.
12. Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019;5:30–6.
13. Zhang Z, Zhou Y, Yang J, et al. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer. 2019;19:511.
14. Cheung KS, Seto WK, Wong DK, et al. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat. 2017;24:654–61.
15. Mak LY, Wong DK, Cheung KS, et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43–54.
16. Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942–7.
17. Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439–45.
18. Lam YF, Seto WK, Wong D, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Transl Gastroenterol. 2017;8:172.
19. Chen EQ, Feng S, Wang ML, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173.
20. Kim BG, Park NH, Lee SB, et al. Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir. J Viral Hepat. 2018;25:1565–75.
21. Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37:995–1001.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.